Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019050313) COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DDIAS INHIBITOR AND DEATH RECEPTOR LIGAND
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/050313 International Application No.: PCT/KR2018/010457
Publication Date: 14.03.2019 International Filing Date: 07.09.2018
IPC:
A61K 48/00 (2006.01) ,A61K 38/19 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
Applicants:
한국생명공학연구원 KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY [KR/KR]; 대전시 유성구 과학로 125 125, Gwahak-ro, Yuseong-gu, Daejeon 34141, KR
Inventors:
원미선 WON, Mi Sun; KR
임주영 IM, Joo-Young; KR
김보경 KIM, Bo Kyung; KR
반현승 BAN, Hyun Seung; KR
정경은 JUNG, Kyeong-Eun; KR
Agent:
특허법인 태평양 BAE, KIM & LEE IP GROUP; 서울시 서초구 강남대로 343, 11층 11th Floor, 343, Gangnam-daero, Seocho-gu, Seoul 06626, KR
Priority Data:
10-2017-011524908.09.2017KR
Title (EN) COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DDIAS INHIBITOR AND DEATH RECEPTOR LIGAND
(FR) COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DU CANCER COMPRENANT UN INHIBITEUR DE DDIAS ET UN LIGAND DE RÉCEPTEUR DE MORT
(KO) DDIAS 억제제 및 사멸 수용체 리간드를 포함하는 암의 예방 또는 치료용 조성물
Abstract:
(EN) The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising a DNA damage-induced apoptosis suppressor (DDIAS) inhibitor and a death receptor ligand as active ingredients. Since the DDIAS inhibitor of the present invention effectively inhibits the degradation promotion of caspase-8 and the formation of the death-inducing signaling complex (DISC) by means of an action of DDIAS, and exhibits an excellent synergistic effect of promoting apoptosis in cancer cells by acting together with the death receptor ligand, the DDIAS inhibitor can be variously used as a composition for prevention and treatment of cancer including lung cancer and liver cancer.
(FR) La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de maladies, comprenant comme principes actifs un inhibiteur du suppresseur de l'apoptose induite par les lésions de l'ADN (DDIAS) et un ligand de récepteur de mort. Du fait que l'inhibiteur de DDIAS de la présente invention inhibe efficacement la promotion de la dégradation de la caspase-8 et la formation du complexe de signalisation induisant la mort (DISC) grâce à l'action de DDIAS, et présente un excellent effet synergique de promotion de l'apoptose dans les cellules cancéreuses en agissant conjointement avec le ligand du récepteur de mort, l'inhibiteur de DDIAS peut être utilisé de diverses manières en tant que composition pour la prévention et le traitement du cancer, y compris le cancer du poumon et le cancer du foie.
(KO) 본 발명은 DDIAS (DNA damage-induced apoptosis suppressor) 억제제 및 사멸 수용체(death receptor) 리간드를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명의 DDIAS 억제제는 DDIAS의 작용에 의한 카스파제(caspase)-8의 분해촉진 및 DISC (death-inducing signaling complex) 형성 억제를 효과적으로 저해하여, 사멸 수용체 리간드와 함께 작용해 암세포에서의 세포 사멸을 촉진하는 우수한 시너지 효과를 발휘함으로써, 폐암 및 간암을 포함한 암의 예방 및 치료용 조성물로 다양하게 활용될 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)